Indolent Lymphoma Treatment Market Report

Global and Region Indolent Lymphoma Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：138
  • REPORT CODE：GMM886204
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Indolent Lymphoma Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Indolent Lymphoma Treatmentmarket, defines the market attractiveness level of Indolent Lymphoma Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Indolent Lymphoma Treatment industry, describes the types of Indolent Lymphoma Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Indolent Lymphoma Treatment market and the development prospects and opportunities of Indolent Lymphoma Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Indolent Lymphoma Treatment market in Chapter 13.

    By Player:

    • Bristol-Myers Squibb Company

    • Juno Therapeutics Inc

    • Incyte Corporation

    • Celgene Corporation

    • Altor BioScience Corporation

    • Astellas Pharma Inc

    • Gilead Sciences

    • Bayer AG

    • Boehringer Ingelheim GmbH

    • Infinity Pharmaceuticals

    • MedImmune

    • Eli Lilly and Company

    • F Hoffmann-La Roche Ltd

    • Amgen Inc

    By Type:

    • BI-836826

    • ALT-803

    • BMS-986016

    • CC-122

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Indolent Lymphoma Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Indolent Lymphoma Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Indolent Lymphoma Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Indolent Lymphoma Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Indolent Lymphoma Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Indolent Lymphoma Treatment Consumption (2017-2022)

    • 7.2 United States Indolent Lymphoma Treatment Consumption (2017-2022)

    • 7.3 Europe Indolent Lymphoma Treatment Consumption (2017-2022)

    • 7.4 China Indolent Lymphoma Treatment Consumption (2017-2022)

    • 7.5 Japan Indolent Lymphoma Treatment Consumption (2017-2022)

    • 7.6 India Indolent Lymphoma Treatment Consumption (2017-2022)

    • 7.7 South Korea Indolent Lymphoma Treatment Consumption (2017-2022)

    8 Region and Country-wise Indolent Lymphoma Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Indolent Lymphoma Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Indolent Lymphoma Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Indolent Lymphoma Treatment Consumption Forecast (2022-2028)

    • 8.4 China Indolent Lymphoma Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Indolent Lymphoma Treatment Consumption Forecast (2022-2028)

    • 8.6 India Indolent Lymphoma Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Indolent Lymphoma Treatment Consumption Forecast (2022-2028)

    9 Global Indolent Lymphoma Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Indolent Lymphoma Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global BI-836826 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global ALT-803 Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global BMS-986016 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global CC-122 Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Indolent Lymphoma Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Indolent Lymphoma Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Indolent Lymphoma Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global BI-836826 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global ALT-803 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global BMS-986016 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global CC-122 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Indolent Lymphoma Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Indolent Lymphoma Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Indolent Lymphoma Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Indolent Lymphoma Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Indolent Lymphoma Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Indolent Lymphoma Treatment Market Competitive Analysis

    • 14.1 Bristol-Myers Squibb Company

      • 14.1.1 Bristol-Myers Squibb Company Company Details

      • 14.1.2 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product and Service

    • 14.2 Juno Therapeutics Inc

      • 14.2.1 Juno Therapeutics Inc Company Details

      • 14.2.2 Juno Therapeutics Inc Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Juno Therapeutics Inc Indolent Lymphoma Treatment Product and Service

    • 14.3 Incyte Corporation

      • 14.3.1 Incyte Corporation Company Details

      • 14.3.2 Incyte Corporation Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Incyte Corporation Indolent Lymphoma Treatment Product and Service

    • 14.4 Celgene Corporation

      • 14.4.1 Celgene Corporation Company Details

      • 14.4.2 Celgene Corporation Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Celgene Corporation Indolent Lymphoma Treatment Product and Service

    • 14.5 Altor BioScience Corporation

      • 14.5.1 Altor BioScience Corporation Company Details

      • 14.5.2 Altor BioScience Corporation Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Altor BioScience Corporation Indolent Lymphoma Treatment Product and Service

    • 14.6 Astellas Pharma Inc

      • 14.6.1 Astellas Pharma Inc Company Details

      • 14.6.2 Astellas Pharma Inc Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Astellas Pharma Inc Indolent Lymphoma Treatment Product and Service

    • 14.7 Gilead Sciences

      • 14.7.1 Gilead Sciences Company Details

      • 14.7.2 Gilead Sciences Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Gilead Sciences Indolent Lymphoma Treatment Product and Service

    • 14.8 Bayer AG

      • 14.8.1 Bayer AG Company Details

      • 14.8.2 Bayer AG Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Bayer AG Indolent Lymphoma Treatment Product and Service

    • 14.9 Boehringer Ingelheim GmbH

      • 14.9.1 Boehringer Ingelheim GmbH Company Details

      • 14.9.2 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product and Service

    • 14.10 Infinity Pharmaceuticals

      • 14.10.1 Infinity Pharmaceuticals Company Details

      • 14.10.2 Infinity Pharmaceuticals Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Infinity Pharmaceuticals Indolent Lymphoma Treatment Product and Service

    • 14.11 MedImmune

      • 14.11.1 MedImmune Company Details

      • 14.11.2 MedImmune Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 MedImmune Indolent Lymphoma Treatment Product and Service

    • 14.12 Eli Lilly and Company

      • 14.12.1 Eli Lilly and Company Company Details

      • 14.12.2 Eli Lilly and Company Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Eli Lilly and Company Indolent Lymphoma Treatment Product and Service

    • 14.13 F Hoffmann-La Roche Ltd

      • 14.13.1 F Hoffmann-La Roche Ltd Company Details

      • 14.13.2 F Hoffmann-La Roche Ltd Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 F Hoffmann-La Roche Ltd Indolent Lymphoma Treatment Product and Service

    • 14.14 Amgen Inc

      • 14.14.1 Amgen Inc Company Details

      • 14.14.2 Amgen Inc Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Amgen Inc Indolent Lymphoma Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Indolent Lymphoma Treatment

    • Figure Indolent Lymphoma Treatment Picture

    • Table Global Indolent Lymphoma Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Indolent Lymphoma Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Indolent Lymphoma Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Indolent Lymphoma Treatment Consumption by Country (2017-2022)

    • Figure United States Indolent Lymphoma Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Indolent Lymphoma Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Indolent Lymphoma Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Indolent Lymphoma Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Indolent Lymphoma Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Indolent Lymphoma Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Indolent Lymphoma Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Indolent Lymphoma Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Indolent Lymphoma Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Indolent Lymphoma Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Indolent Lymphoma Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Indolent Lymphoma Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Indolent Lymphoma Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global BI-836826 Consumption and Growth Rate (2017-2022)

    • Figure Global ALT-803 Consumption and Growth Rate (2017-2022)

    • Figure Global BMS-986016 Consumption and Growth Rate (2017-2022)

    • Figure Global CC-122 Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global BI-836826 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ALT-803 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global BMS-986016 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CC-122 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Indolent Lymphoma Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Indolent Lymphoma Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table Bristol-Myers Squibb Company (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Company Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product and Service

    • Table Juno Therapeutics Inc (Foundation Year, Company Profile and etc.)

    • Table Juno Therapeutics Inc Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Juno Therapeutics Inc Indolent Lymphoma Treatment Product and Service

    • Table Incyte Corporation (Foundation Year, Company Profile and etc.)

    • Table Incyte Corporation Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Incyte Corporation Indolent Lymphoma Treatment Product and Service

    • Table Celgene Corporation (Foundation Year, Company Profile and etc.)

    • Table Celgene Corporation Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene Corporation Indolent Lymphoma Treatment Product and Service

    • Table Altor BioScience Corporation (Foundation Year, Company Profile and etc.)

    • Table Altor BioScience Corporation Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Altor BioScience Corporation Indolent Lymphoma Treatment Product and Service

    • Table Astellas Pharma Inc (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma Inc Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Inc Indolent Lymphoma Treatment Product and Service

    • Table Gilead Sciences (Foundation Year, Company Profile and etc.)

    • Table Gilead Sciences Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences Indolent Lymphoma Treatment Product and Service

    • Table Bayer AG (Foundation Year, Company Profile and etc.)

    • Table Bayer AG Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer AG Indolent Lymphoma Treatment Product and Service

    • Table Boehringer Ingelheim GmbH (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product and Service

    • Table Infinity Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Infinity Pharmaceuticals Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Infinity Pharmaceuticals Indolent Lymphoma Treatment Product and Service

    • Table MedImmune (Foundation Year, Company Profile and etc.)

    • Table MedImmune Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table MedImmune Indolent Lymphoma Treatment Product and Service

    • Table Eli Lilly and Company (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly and Company Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly and Company Indolent Lymphoma Treatment Product and Service

    • Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Ltd Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Indolent Lymphoma Treatment Product and Service

    • Table Amgen Inc (Foundation Year, Company Profile and etc.)

    • Table Amgen Inc Indolent Lymphoma Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Inc Indolent Lymphoma Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US